Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AEterna Zentaris Inc (NASDAQ:AEZS)

1.88
Delayed Data
As of Aug 18
 +0.01 / +0.53%
Today’s Change
0.78
Today|||52-Week Range
5.59
-47.78%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$29.7M

Company Description

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Montreal, Canada.

Contact Information

Æterna Zentaris, Inc.
1 Place Marie
Montréal Qubec H3B 1R1
P:(514) 847-4747
Investor Relations:
(843) 900-3211

Employees

Shareholders

Other institutional4.64%
Mutual fund holders0.08%
Individual stakeholders--

Top Executives

Michael WardChief Executive Officer
Geneviève LemaireChief Accounting Officer & Vice President-Finance
Michael TeifelVice President-Pre-Clinical Development
Richard SachseSenior VP, Chief Scientific & Medical Officer
Jude DingesChief Commercial Officer & Senior Vice President